Article
Identification of novel F508del-CFTR traffic correctors among triazole derivatives.
European journal of pharmacology - 5 Jan 2023
Bacalhau Mafalda, Ferreira Filipa C, Kmit Arthur, Souza Felipe R, da Silva Verônica D, Pimentel André S, Amaral Margarida D, Buarque Camilla D, Lopes-Pacheco Miquéias
Abstract excerpt
The most prevalent cystic fibrosis (CF)-causing mutation - F508del - impairs the folding of CFTR protein, resulting in its defective trafficking and premature degradation. Small molecules termed correctors may rescue F508del-CFTR and therefore constitute promising pharmacotherapies acting on the fundamental cause of the disease. Here, we screened a collection of triazole compounds to identify novel F508del-CFTR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.